A Dose Adjusted, Open Label, Multi-Centre Study to Determine the Safety, Tolerability and Pharmacokinetics of STC3141 Administered as an Infusion forup to 72 hours in Subjects with Sepsis and Normal or Compromised Renal Function in an Intensive Care Unit (REFINE) (ACTRN12620000716965)

REFINE

This study is no longer recruiting patients. The following details are for information only.
This trial is Recently completed/closed
Registration number ACTRN12620000716965

Program & service

This trial is being run with the Intensive Care Services service, and as part of the Intensive Care program.

Trial phase

Phase 1

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principle investigator

Professor Andrew Udy

More information

To find out more about this clinical trial, please review full details on the ANZCTR website.

View on ANZCTR

If you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.